Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03043872
Title Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung small cell carcinoma

Therapies

Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab

Carboplatin + Cisplatin + Durvalumab + Etoposide

Carboplatin + Cisplatin + Etoposide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.